TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29876926

Group type: EXPERIMENTAL
Intervention: Inflated praise
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Modest praise
Number of subjects: 105

Group type: COMPARATOR
Intervention: No praise
Number of subjects: 105
Study: 27687452

Group type: EXPERIMENTAL
Intervention: Boussignac CPAP
Number of subjects: 24

Group type: COMPARATOR
Intervention: Venturi mask
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Boussignac CPAP and Venturi mask
Number of subjects: 24
Study: 24629989

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/d for 30 days (group 1)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg/d for 30 days (group 2)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/d (group 1)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Clopidogrel 150 mg/d (group 2)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Both groups (1 and 2)
Number of subjects: 99
Study: 22187203

Group type: EXPERIMENTAL
Intervention: SM-11355
Number of subjects: 122

Group type: COMPARATOR
Intervention: Zinostatin stimalamer
Number of subjects: 122
Study: 20683333

Group type: EXPERIMENTAL
Intervention: Sevoflurane volatile induction/maintenance anaesthesia (Group VIMA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Propofol-remifentanil total intravenous anaesthesia (Group TIVA)
Number of subjects: 64
Study: 19167593

Group type: EXPERIMENTAL
Intervention: NXY-059 (8-hour IV infusion with a 1-hour loading dose at 3x maintenance rate)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 36
Study: 15891344

Group type: EXPERIMENTAL
Intervention: Sufentanil-midazolam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketamine-midazolam
Number of subjects: 30
Study: 12651648

Group type: EXPERIMENTAL
Intervention: Ginger (Zingiber officinale)
Number of subjects: 180
Study: 11340136

Group type: EXPERIMENTAL
Intervention: Automated biopsy device
Number of subjects: 56

Group type: COMPARATOR
Intervention: Aspiration technique
Number of subjects: 56
Study: 9175409

Group type: EXPERIMENTAL
Intervention: Questionnaire with four pages (22 questions)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Questionnaire with eight pages (35 questions)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Follow-up mailings
Number of subjects: 3000
Study: 8242282

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 2.5 l of a 2.5% glucose/0.45% NaCl solution
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo infusion of 100 ml 0.9% NaCl
Number of subjects: 66
Study: 2939214

Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg twice daily)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg twice daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ketanserin and Pindolol
Number of subjects: 17
Study: 30465360

Group type: EXPERIMENTAL
Intervention: Sildenafil alone (2 mg/kg per dose, three times a day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sildenafil plus Bosentan (Sildenafil: 2 mg/kg per dose, three times a day; Bosentan: 1 mg/kg per dose, twice a day)
Number of subjects: 100
Study: 27581574

Group type: EXPERIMENTAL
Intervention: Micronutrient adequacy (MMDA) and dietary diversity scores
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Consumption of 'sentinel foods' (iron rich, fortified, animal source, dairy)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: MMDA calcium, iron, zinc, and dietary diversity
Number of subjects: 811
Study: 24923683

Group type: EXPERIMENTAL
Intervention: Colloid-based therapy
Number of subjects: 2857

Group type: COMPARATOR
Intervention: Crystalloid-based therapy
Number of subjects: 2857
Study: 22070352

Group type: EXPERIMENTAL
Intervention: Daily consumption of apple (1-128 g), doubling every 2-3 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 20179229

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 90

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 18194591

Group type: EXPERIMENTAL
Intervention: Carisoprodol 250-mg tablets
Number of subjects: 562

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 562
Study: 15932830

Group type: EXPERIMENTAL
Intervention: IV fluid bolus of 1,000 mL
Number of subjects: 142

Group type: COMPARATOR
Intervention: IV fluid bolus of 500 mL
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Lateral positioning (left and right)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Oxygen administration at 10 L/min via nonrebreather face mask
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Oxygen administration for fetuses with FSpO(2) < 40%
Number of subjects: 142

Group type: COMPARATOR
Intervention: Oxygen administration for fetuses with FSpO(2) ≥ 40%
Number of subjects: 142
Study: 12502669

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 40
Study: 12109341

Group type: COMPARATOR
Intervention: Dietary supplements (androstenedione, beta-carotene, CoQ10, garlic, soy, vitamin C and E)
Number of subjects: 0
Study: 11107583

Group type: EXPERIMENTAL
Intervention: Measurement of antiacetylcholine receptor antibodies
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Electrophysiological investigations
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Correlation with clinical type of myasthenia
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Diagnostic value of acetylcholine receptor antibodies measurement
Number of subjects: 63
Study: 8750768

Group type: EXPERIMENTAL
Intervention: 2 mg of glipizide given 30 min before glucose ingestion
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 5 mg of glipizide ingested at 120 min during euglycemic insulin clamps
Number of subjects: 19
Study: 2406298

Group type: EXPERIMENTAL
Intervention: Nicardipine 90 mg/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7362734

Group type: EXPERIMENTAL
Intervention: 75 mg nomifensine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 50 mg amitriptyline
Number of subjects: 6
Study: 6437877

Group type: EXPERIMENTAL
Intervention: 50 mg Epostane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 100 mg Epostane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29471206

Group type: EXPERIMENTAL
Intervention: Music therapy (n = 204)
Number of subjects: 409

Group type: COMPARATOR
Intervention: No music therapy (n = 205)
Number of subjects: 409
Study: 27888984

Group type: EXPERIMENTAL
Intervention: Minimal home-based psychoeducative intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study: 23990230

Group type: EXPERIMENTAL
Intervention: Heart Failure Patients
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control Group (General Population without HF)
Number of subjects: 70
Study: 22889444

Group type: EXPERIMENTAL
Intervention: Uncoated paper
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disposable underpad
Number of subjects: 0
Study: 18768358

Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate (WPI(HD))
Number of subjects: 28

Group type: COMPARATOR
Intervention: Flavoured water (FW)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Whey protein isolate (WPI)
Number of subjects: 28
Study: 18207408

Group type: EXPERIMENTAL
Intervention: Endoscopic endonasal transsphenoidal surgery
Number of subjects: 78
Study: 15672030

Group type: EXPERIMENTAL
Intervention: Plasma volume expansion (250 mL hydroxyethyl starch 6% twice daily in 4 hours, and NaCl 0.9% between doses)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (NaCl 0.9% when necessary with medication)
Number of subjects: 216
Study: 14683655

Group type: EXPERIMENTAL
Intervention: Whole virus vaccine (7.5 microg, 15 microg, or 30 microg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subunit vaccine (7.5 microg, 15 microg, or 30 microg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Whole virus vaccine (one dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subunit vaccine (one dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Whole virus and subunit vaccines (two doses)
Number of subjects: 60
Study: 10953489

Group type: EXPERIMENTAL
Intervention: Burch colposuspension and paravaginal defect repair
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vaginal examination
Number of subjects: 16
Study: 8666620

Group type: EXPERIMENTAL
Intervention: Stanmore prosthesis
Number of subjects: 413

Group type: COMPARATOR
Intervention: Charnley prosthesis
Number of subjects: 413
Study: 1283117

Group type: EXPERIMENTAL
Intervention: 1 mg/day finasteride
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 5 mg/day finasteride
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2952396

Group type: EXPERIMENTAL
Intervention: 500 mg of vitamin C daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31840323

Group type: EXPERIMENTAL
Intervention: Nutrition orientation and a normoproteic, normocaloric nutrition supplement (group 2)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Nutrition orientation and the nutritional supplement with TGF‐Î²2 (group 3)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nutrition orientation only (group 1)
Number of subjects: 38
Study: 29931392

Group type: EXPERIMENTAL
Intervention: Modified Robert Jones bandage (MRJB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-compressive dressing (NCD)
Number of subjects: 80
Study: 26899523

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24195841

Group type: EXPERIMENTAL
Intervention: Health messages related to diet
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Health messages related to physical activity
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Messages related to meals and providing food to people in need
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Physical activity messages related to praise dancing
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Media types for health messages
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Source of health messages
Number of subjects: 1109
Study: 22318328

Group type: EXPERIMENTAL
Intervention: Re-irradiation with a total dose of 50 Gy (25 fractions over 5 weeks) combined with 900 mg/m²/day capecitabine
Number of subjects: 31
Study: 20484828

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group (no EPA)
Number of subjects: 223
Study: 18302607

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia (CBT-I) including stimulus control instructions, sleep restriction therapy, and sleep education and hygiene.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Component control group receiving sleep education and hygiene only.
Number of subjects: 72
Study: 15943846

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg/day for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mosapride citrate 15 mg/day for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline 30 mg/day for 4 weeks (second-step therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No medication (control for second-step therapy)
Number of subjects: 0
Study: 14598618

Group type: EXPERIMENTAL
Intervention: remifentanil (1 microgram/kg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ketamine (0.7 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study: 10807895

Group type: EXPERIMENTAL
Intervention: Hydrothermally processed cereals (active treatment)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Ordinary cereals (placebo treatment)
Number of subjects: 53
Study: 8799657

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 636

Group type: COMPARATOR
Intervention: Control group (non-smokers)
Number of subjects: 636
Study: 1324557

Group type: EXPERIMENTAL
Intervention: NGM/EE triphasic
Number of subjects: 4234

Group type: COMPARATOR
Intervention: LNG/EE triphasic
Number of subjects: 4234
Study: 6337196

Group type: EXPERIMENTAL
Intervention: 20-component timothy extract
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: two-component timothy extract
Number of subjects: 40
Study: 28946539

Group type: EXPERIMENTAL
Intervention: Dynamic upper extremity exercise with breathing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Breathing exercise only (Control)
Number of subjects: 40
Study: 27306393

Group type: EXPERIMENTAL
Intervention: Nasal expiratory positive airway pressure (EPAP)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nasal expiratory positive airway pressure (EPAP) for ≥ 3 h
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no EPAP)
Number of subjects: 19
Study: 26150052

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 109
Study: 21914148

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam 0.015 mg/kg (Group S)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No sedation (Group NS)
Number of subjects: 78
Study: 19937027

Group type: EXPERIMENTAL
Intervention: Doxorubicin DEB-TACE
Number of subjects: 84

Group type: COMPARATOR
Intervention: Bland embolization
Number of subjects: 84
Study: 18983646

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) with semi-automatic border detection
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard echocardiographic parameters of dyssynchrony
Number of subjects: 45
Study: 16857659

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol valerate continuously with an addition of 10 mg medroxyprogesterone acetate (MPA) during the last 12 days of the 28‐day cycle
Number of subjects: 106
Study: 12823267

Group type: EXPERIMENTAL
Intervention: Dinner with four glasses of red wine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dinner with four glasses of beer
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dinner with four glasses of spirits (Dutch gin)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dinner with sparkling mineral water (control)
Number of subjects: 11
Study: 10805891

Group type: EXPERIMENTAL
Intervention: Male donor-female recipient transplants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sex-matched (male to male) control explants
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Allografts
Number of subjects: 40
Study: 9015114

Group type: EXPERIMENTAL
Intervention: RIT 4237 bovine rotavirus vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bovine and rhesus rotavirus vaccines (meta-analysis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bovine and rhesus rotavirus vaccines
Number of subjects: 0
Study: 2002864

Group type: EXPERIMENTAL
Intervention: Liquid nitrogen
Number of subjects: 93

Group type: COMPARATOR
Intervention: Histofreezer
Number of subjects: 93
Study: 6829497

Group type: EXPERIMENTAL
Intervention: Continuous vindesine (1.2 mg/m2, 5-day infusion, every 3 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Continuous vinblastine (1.5 mg/m2/day, every 3 weeks)
Number of subjects: 33
Study: 30856418

Group type: EXPERIMENTAL
Intervention: Complex language (passive voice)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Simpler language (active voice)
Number of subjects: 42
Study: 29436854

Group type: EXPERIMENTAL
Intervention: Active mother's voice exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive mother's voice exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infants with brain injury
Number of subjects: 0
Study: 25449552

Group type: EXPERIMENTAL
Intervention: BRO HIV/STI risk‐reduction intervention
Number of subjects: 595

Group type: COMPARATOR
Intervention: Attention-matched control intervention
Number of subjects: 595
Study: 23319285

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic (SIL) right colectomy
Number of subjects: 159

Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL) right colectomy
Number of subjects: 159
Study: 21114656

Group type: EXPERIMENTAL
Intervention: belatacept‐mycophenolate mofetil (MMF)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: belatacept‐sirolimus (SRL)
Number of subjects: 89

Group type: COMPARATOR
Intervention: TAC‐MMF
Number of subjects: 89
Study: 19861106

Group type: EXPERIMENTAL
Intervention: Presence of clowns during surgery
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no clowns)
Number of subjects: 61
Study: 17827354

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 99

Group type: COMPARATOR
Intervention: sulfadoxine-pyrimethamine (SP)
Number of subjects: 99
Study: 15598790

Group type: EXPERIMENTAL
Intervention: 30 g of alcohol daily (two drinks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: 0 g of alcohol (control)
Number of subjects: 31
Study: 11829198

Group type: EXPERIMENTAL
Intervention: ISDN ointment (13.4 +/- 3.61 mg ISDN)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9780281

Group type: EXPERIMENTAL
Intervention: G‐CSF alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both G‐CSF and rifabutin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rifabutin alone
Number of subjects: 30
Study: 8537705

Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg orally
Number of subjects: 53

Group type: COMPARATOR
Intervention: Rifampicin therapy
Number of subjects: 53
Study: 2320489

Group type: EXPERIMENTAL
Intervention: Sponging plus acetaminophen
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sponging alone
Number of subjects: 73

Group type: COMPARATOR
Intervention: Acetaminophen alone
Number of subjects: 73
Study: 656286

Group type: EXPERIMENTAL
Intervention: Digoxin solution alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Three intact capsules containing digoxin solution
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Three capsules containing digoxin solution sectioned in half
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Three capsules containing digoxin solution dissolved in water prior to administration
Number of subjects: 8
Study: 31666651

Group type: EXPERIMENTAL
Intervention: Attachment-based compassion therapy (ABCT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 34
Study: 26703291

Group type: EXPERIMENTAL
Intervention: Wavefront-guided PRK (Visx Star S4 Customvue)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Wavefront-optimized PRK (Allegretto Wave Eye-Q 400 Hz)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Wavefront-guided PRK
Number of subjects: 108

Group type: COMPARATOR
Intervention: Wavefront-optimized PRK
Number of subjects: 108
Study: 24293605

Group type: EXPERIMENTAL
Intervention: Flexible casts that can be removed at home
Number of subjects: 317

Group type: COMPARATOR
Intervention: Traditional management using a cast conventionally removed in hospital
Number of subjects: 317
Study: 20927574

Group type: EXPERIMENTAL
Intervention: Intervention (Toolkit distributed via direct mail)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control
Number of subjects: 209
Study: 19568027

Group type: EXPERIMENTAL
Intervention: 3 days of high-dose intravenous therapy followed by 3 weeks of oral therapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 5 days or less intravenous treatment
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Temperature and C-reactive protein monitoring
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Shortened course of intravenous and oral antibiotic therapy
Number of subjects: 70
Study: 16766444

Group type: EXPERIMENTAL
Intervention: Proper names with distractors (associate condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Common names with distractors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proper names with distractors (identical condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distractors belonging to a different professional category (different condition)
Number of subjects: 0
Study: 14722627

Group type: EXPERIMENTAL
Intervention: Calcium citrate (1000 mg/day for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Calcium carbonate (1000 mg/day for 12 weeks)
Number of subjects: 40
Study: 11218025

Group type: EXPERIMENTAL
Intervention: Disc degeneration classified from MR images
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Progressive degeneration
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Loss of disc height classified from MR images
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: First sign of disc degeneration (moderate loss of nucleus signal)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Progress of degeneration
Number of subjects: 43
Study: 9362381

Group type: EXPERIMENTAL
Intervention: Interferon alfa (IFN‐alpha) treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 90
Study: 1391264

Group type: EXPERIMENTAL
Intervention: TPN with lipids
Number of subjects: 17

Group type: COMPARATOR
Intervention: Glucose group (control)
Number of subjects: 17
Study: 4010919

Group type: EXPERIMENTAL
Intervention: Ambulant group (no bed rest for 24h)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Bed rest group (confined to bed for 24h)
Number of subjects: 352
Study: 30650569

Group type: EXPERIMENTAL
Intervention: Previous first-aid training (32%)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Self-reported confidence in subway safety
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Socio-demographic characteristics (female, lower income, unmarried)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Correct fire-related health response knowledge
Number of subjects: 1000
Study: 29332752

Group type: EXPERIMENTAL
Intervention: Multi-modal mobilization
Number of subjects: 68

Group type: COMPARATOR
Intervention: Routine physiotherapy
Number of subjects: 68
Study: 26333526

Group type: EXPERIMENTAL
Intervention: Kiosk-based health communication intervention
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 450
Study: 24796334

Group type: EXPERIMENTAL
Intervention: Closed minimal extracorporeal circulation (MECC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional open extracorporeal circulation (CECC)
Number of subjects: 20